Compare HDB & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HDB | SNY |
|---|---|---|
| Founded | 1994 | 1994 |
| Country | India | France |
| Employees | N/A | 74846 |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 130.3B | 107.3B |
| IPO Year | 2002 | N/A |
| Metric | HDB | SNY |
|---|---|---|
| Price | $26.77 | $47.70 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $58.00 |
| AVG Volume (30 Days) | ★ 12.2M | 2.9M |
| Earning Date | 04-18-2026 | 04-23-2026 |
| Dividend Yield | 1.44% | ★ 3.40% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $3.86 |
| Revenue Next Year | $8.77 | $5.64 |
| P/E Ratio | $18.92 | ★ $6.14 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $23.91 | $43.32 |
| 52 Week High | $79.62 | $55.73 |
| Indicator | HDB | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 47.17 | 59.24 |
| Support Level | $23.91 | $46.88 |
| Resistance Level | $37.18 | $48.88 |
| Average True Range (ATR) | 0.59 | 0.74 |
| MACD | 0.44 | 0.11 |
| Stochastic Oscillator | 78.07 | 75.19 |
HDFC Bank Ltd is an Indian bank. It operates in the following segments: Treasury, Retail banking, Wholesale banking, and Other banking business. The maximum revenue for the company is generated from its Retail banking segment, which serves retail customers through its branch network and other channels. This segment raises customer deposits and provides loans and other services to customers using different product groups. Its other operations include providing wholesale banking services to corporates, government entities, and other enterprises, generating income from its treasury operations, and performing para-banking activities such as offering credit cards, debit cards, etc. Geographically, the company generates a majority of its revenue from its operations in India.
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.